Calidi Reports Third-Quarter Net Loss of 3.6 Million Dollars as Lead Candidate CLD-401 Advances Toward Clinic
In San Diego, California, biotechnology company Calidi Biotherapeutics reported on November 13 its financial and operating results for the three months ended September 30, 2026. The net loss attributable to common stockholders for the quarter was 3.6 million dollars. During the quarter the company received 1.2 million dollars in gross proceeds from an at-the-market registered direct offering.
On research, CLD-401, the lead candidate from the company RedTail platform, continued to progress toward the clinic and remains in IND-enabling studies. It targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types. The company said CLD-401 demonstrated anti-tumor activity with systemic administration in syngeneic tumor models.
RedTail is a systemically delivered virotherapy platform featuring an engineered enveloped oncolytic virus designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.
On scientific exchange, the company presented two posters at the European Society for Medical Oncology Congress 2026 on October 24, showcasing data from the RedTail platform, and presented preclinical data from its in situ T-cell engager platform, including the TROP-2-targeted candidate CLD-501 and the EpCAM-targeted candidate CLD-502.
Calidi said it continued throughout the third quarter to advance the RedTail platform for systemic and local delivery. The release gave no financial guidance for the coming quarter.
Source: Calidi Biotherapeutics
Published by GSM · USA (original Chinese edition)
Photo: 图：溶瘤病毒改造肿瘤微环境的机制示意图。作者：Antonio Marchini，CC BY 4.0，维基共享资源。 / Photo: Schematic of an oncolytic virus remodeling the tumor microenvironment. Credit: Antonio Marchini, CC BY 4.0, via Wikimedia Commons.
Syntec Optics Third-Quarter Revenue Rises 23 Percent to Record 8.5 Million Dollars With Net Income Turning Positive at 246,574 Dollars and Space Tech Revenue Up 117 Percent2026-11-14
Knightscope Third-Quarter Revenue Rises 177 Percent to 8.7 Million Dollars With Service Revenue of 8.6 Million and Net Loss of 11.8 Million2026-11-14